Subjective visual horizontal during follow-up after unilateral vestibular deafferentation with gentamicin.
The subjective visual horizontal (SVH) was measured by means of a small, rotatable, luminous line in darkness in the upright head and body position and at 10, 20 and 30 degrees of tilt to the right and left before, and repeatedly during a follow-up period of 1 year after intratympanic gentamicin instillations in 12 patients with recurrent vertigo attacks. This treatment caused a loss of the bithermal caloric responses on the diseased side. Shortly after treatment there was a significant tilt of SVH towards the treated side (group mean = 10.6 degrees). Repeated testing made it possible to characterize mathematically the changes with time for SVH. For the group of patients as a whole this otolithic component of vestibular compensation was best described by a power function, SVH = 8.65t(-0.16) degrees, where t is time in days after maximum tilt of SVH. After 1 year, SVH was still significantly tilted towards the treated side (group mean = 3.16 degrees). Gentamicin treatment also caused a significant reduction in the perception of head and body tilt towards the deafferented side, while the perception of tilt towards the healthy side did not show any significant changes. During follow-up there was a gradual improvement in the perception of tilt towards the treated side. However, a significant asymmetry in roll-tilt perception was still present 1 year after deafferentation. There was no correlation between SVH in the upright position and roll-tilt perception, suggesting that these parameters are to some extent dependent on different afferent input from the vestibular organ. They were also found to be complementary for the detection of vestibular disturbance.
Tribukait
A
A
Department of Audiology, Karolinska Hospital, Stockholm, Sweden.
Bergenius
J
J
Brantberg
K
K
D000344:Afferent Pathways / Q000502:physiology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002150:Caloric Tests; D004585:Electrooculography; D005260:Female; D005500:Follow-Up Studies; D005839:Gentamicins / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000628:therapy; D008875:Middle Aged; D013997:Time Factors; D014717:Vertigo / Q000628:therapy*; D014724:Vestibular Function Tests; D014722:Vestibule, Labyrinth / Q000187:drug effects / Q000503:physiopathology*; D014796:Visual Perception / Q000502:physiology*
D000900:Anti-Bacterial Agents; D005839:Gentamicins